• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Rhythm Pharmaceuticals Receives European Medicines Agency PRIME Designation for Setmelanotide in Rare Genetic Disorders of Obesity

    Jocelyn Aspa
    Jul. 23, 2018 08:51AM PST
    Pharmaceutical Investing

    Rhythm Pharmaceuticals (NASDAQ:RYTM) has announced that the European Agency (EMA) has granted PRIority MEdicines (PRIME) designation for the company’s melanocortin-4 receptor (MC4R) for the treatment of obesity and the control of hunger associated with deficiency disorders of the MC4R pathway. As quoted in the press release: The PRIME program was launched by the EMA in …

    Rhythm Pharmaceuticals (NASDAQ:RYTM) has announced that the European Agency (EMA) has granted PRIority MEdicines (PRIME) designation for the company’s melanocortin-4 receptor (MC4R) for the treatment of obesity and the control of hunger associated with deficiency disorders of the MC4R pathway.

    As quoted in the press release:

    The PRIME program was launched by the EMA in 2016 to provide early and enhanced support to optimize the development of eligible medicines, speed up their evaluation, and contribute to timely patient access. To be eligible for PRIME, medicines must address an unmet medical need and preliminary data must be available showing the potential to address this need and bring a major therapeutic advantage to patients.

    “We are pleased to receive PRIME designation, which allows us the opportunity to engage more closely with the EMA and potentially accelerate our clinical development of setmelanotide in the European Union,” said Keith Gottesdiener, M.D., Chief Executive Officer of Rhythm Pharmaceuticals. “The receipt of PRIME designation for setmelanotide further validates the fact that people living with rare genetic disorders of obesity are severely underserved by current treatments, which fail to address underlying disease biology. We look forward to working closely with the EMA through our pivotal-stage clinical research to deliver a potentially transformative treatment option to patients.”

    Rhythm has completed pivotal enrollment in two ongoing Phase 3 clinical trials evaluating setmelanotide in pro-opiomelanocortin (POMC) and leptin receptor (LEPR) deficiency obesity and expects to report initial data in the third quarter of 2019. The Company is also evaluating setmelanotide in four additional rare genetic disorders of obesity, including Bardet-Biedl Syndrome (BBS), Alström Syndrome, POMC and other MC4R pathway heterozygous deficiency obesities, and POMC epigenetic disorders. Rhythm plans to initiate a Phase 3 trial of setmelanotide in BBS and Alström Syndrome by the end of 2018, and intends to continue enrolling patients with POMC and other MC4R pathway heterozygous deficiency obesities, as well as POMC epigenetic disorders, in its ongoing Phase 2 basket studies, in order to identify those patients most likely to benefit from setmelanotide treatment.

    Click here to read the full press release.

    pharmaceutical investingnasdaq:rytmrhythm pharmaceuticals
    The Conversation (0)

    Go Deeper

    AI Powered

    Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3

    aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT Study in Late-Breaking Oral Abstract at the European Respiratory Society Congress 2025

    Latest News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Cardiol Therapeutics

    CRDL:CA

    Invion Limited

    IVX:AU

    Principal Technologies

    PTEC:CC
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES